These advancements are the result of new equipment and recently employed protocols at the Company’s R&D headquarters, based in Michigan.
These advancements are the result of new equipment and recently employed protocols at the Company’s R&D headquarters, based in Michigan. These new approaches build on the existing protocols, but allow the Company to increase processing efficiency significantly. The Company expects to see higher throughput as this approach should result in shorter times to generate new transgenics. What previously took an entire day to complete can now be done in a matter of minutes.
The Company expects that, with these new methods, it will be able to drastically accelerate the pace of development for next generation recombinant spider silk fibers and technologies, but does not affect the opening of the Company’s aggressive production operations through its Vietnamese subsidiary, Prodigy Textiles. The Company expects to provide an update on its progress at Prodigy Textiles in the near future.
“As we continue to make significant progress commercializing and scaling production of our existing recombinant spider silk offerings, our research team, led by Dr. Trevor Kane, remains focused on the creation of the next evolution of high performance spider silk materials,” said COO, Jon Rice. “The new processes and equipment implemented today play a key role in that work, allowing for major increases in throughput and what we expect to be faster development cycles.”
To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180918005334/en/
Source: Kraig Biocraft Laboratories, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20180918005334/en
